Search hospitals > South Dakota > Rapid City
Rapid City Regional Hospital
Claim this profileRapid City, South Dakota 57701
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Relapse
Conducts research for Stomach Cancer
397 reported clinical trials
11 medical researchers
Summary
Rapid City Regional Hospital is a medical facility located in Rapid City, South Dakota. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Relapse, Stomach Cancer and other specialties. Rapid City Regional Hospital is involved with conducting 397 clinical trials across 411 conditions. There are 11 research doctors associated with this hospital, such as Abdel-Ghani Azzouqa, Helen L. Frederickson, Bhaskar Purushottam, and Alexander Schabauer.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Abdel-Ghani AzzouqaRapid City Regional Hospital1 year of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
22 reported clinical trials
65 drugs studied
Helen L. FredericksonRapid City Regional Hospital6 years of reported clinical research
Studies Stomach Cancer
Studies Ovarian Cancer
3 reported clinical trials
4 drugs studied
Bhaskar PurushottamMonument Health4 years of reported clinical research
Studies Coronary Artery Disease
Studies Cardiovascular Disease
3 reported clinical trials
4 drugs studied
Alexander SchabauerMonument Health Rapid City Hospital4 years of reported clinical research
Studies Obesity
Studies Heart Failure
2 reported clinical trials
4 drugs studied
Clinical Trials running at Rapid City Regional Hospital
Skin Cancer
Breast Cancer
Lung Cancer
Liver Cancer
Cancer
Esophageal cancer
Stomach Cancer
Heart Failure
Esophageal Cancer
Oropharyngeal Carcinoma
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting2 awards Phase 3
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Rapid City Regional Hospital?
Rapid City Regional Hospital is a medical facility located in Rapid City, South Dakota. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Relapse, Stomach Cancer and other specialties. Rapid City Regional Hospital is involved with conducting 397 clinical trials across 411 conditions. There are 11 research doctors associated with this hospital, such as Abdel-Ghani Azzouqa, Helen L. Frederickson, Bhaskar Purushottam, and Alexander Schabauer.
Where is Rapid City Regional Hospital located?
**Rapid City Regional Hospital**
Location: 353 Fairmont Boulevard, Rapid City, South Dakota. Access is available from Fifth Street or Third Street via Fairmont Boulevard.
Who should I call to ask about financial aid or insurance network?
For billing and insurance-related questions at Rapid City Regional Hospital, part of Monument Health, contact the Patient Financial Services department at 605-755-2455. They offer assistance with understanding care costs, insurance coverage, payment options, and setting up payment plans for those unable to pay the full bill amount. Monument Health also provides Financial Assistance Programs for qualifying patients, which may significantly reduce or eliminate the cost of services. Applications for financial assistance are available in multiple languages and can be submitted through MyChart, by phone, or in person at any Monument Health Hospital or Clinic's Admission/Registration or Emergency Department.
What insurance does Rapid City Regional Hospital accept?
Rapid City Regional Hospital, part of Monument Health, accepts all major insurances. Patients are advised to verify with their insurance provider that Monument Health is in-network. Monument Health participates in Medicaid programs for South Dakota, Minnesota, Montana, Nebraska, and Wyoming, and offers a Financial Assistance Program for eligible care.
What awards or recognition has Rapid City Regional Hospital received?
Rapid City Regional Hospital, part of Monument Health, boasts a 5-star rating from the Centers for Medicare & Medicaid Services (CMS) and has earned numerous accolades including the Joint Commission's Gold Seal of Approval and ENERGY STAR certification. It has been recognized as a top 100 rural hospital in America and has received awards such as the ACTION Registry Platinum Performance Achievement Award and the Get With The Guidelines® Stroke Gold Plus Quality Achievement Award from the American Heart Association. The hospital is also a MBSAQIP Accredited Comprehensive Center, has ISCD Accreditation for its DXA department, and was honored with the Equity of Care, Small/Rural Hospital Excellence Award from the American Hospital Association in 2023.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.